MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingBusiness Wire • 03/05/24
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq ListingBusiness Wire • 02/13/24
MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment DrugAccesswire • 12/29/23
MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024MCAP MediaWire • 12/11/23
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid ArthritisBusiness Wire • 12/06/23
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory PainBusiness Wire • 10/19/23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023Business Wire • 10/04/23
FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)Business Wire • 08/14/23
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial ResultsBusiness Wire • 08/02/23
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related FrailtyBusiness Wire • 07/31/23
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness Wire • 04/12/23
MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid ArthritisBusiness Wire • 03/20/23
MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent TrollsBusiness Wire • 03/08/23
MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed ChemicalBusiness Wire • 03/02/23
MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual MeetingBusiness Wire • 02/28/23
ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022Business Wire • 12/06/22
MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022Business Wire • 12/06/22
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) CongressBusiness Wire • 11/17/22
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug ResearchBusiness Wire • 11/14/22
MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ CompoundBusiness Wire • 08/30/22
Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological SciencesBusiness Wire • 08/03/22
MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness Wire • 07/26/22
MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic ConditionsBusiness Wire • 07/12/22